Results 1 to 10 of about 125,430 (289)
Controlling secretion to limit chemoresistance [PDF]
Genes & Development, 2016 The tumor microenvironment influences cancer progression and therapy outcome by mechanisms not yet fully understood. In this issue, Bent et al. (2016) show how chemotherapy causes endothelial senescence.
Georgilis, A, Gil, J
core +6 more sources
USP29 and SMURF1 orchestrate FSP1-mediated ferroptosis suppression to facilitate chemoresistance in gastric cancer. [PDF]
Nat CommunGastric cancer (GC) ranks as the third leading cause of cancer-related mortality. Chemoresistance poses a major obstacle to successful treatment for GC patients. Here, we demonstrate that ferroptosis suppressor protein 1 (FSP1) enables chemoresistance in
Wu Z +8 more
europepmc +2 more sources
KLF4 in cancer chemoresistance: molecular mechanisms and therapeutic implications. [PDF]
Discov OncolChemoresistance is a major obstacle in cancer treatment, and it often results in treatment failure and disease progression. Among the plethora of factors contributing to chemoresistance, the transcription factor Krüppel-like factor 4 (KLF4) has emerged ...
Yadav SS +6 more
europepmc +2 more sources
Mechanisms of Resistance to Chemotherapy in Hypopharyngeal Carcinoma. [PDF]
BiomedicinesHypopharyngeal carcinoma (HPC) represents the most prognostically unfavorable subtype among head and neck malignancies. Platinum-based neoadjuvant chemotherapy serves as a critical therapeutic approach for improving outcomes in hypopharyngeal carcinoma ...
Lu Z, Qiang Z, Lei W, Cai Z.
europepmc +2 more sources
miR-200c sensitizes breast cancer cells to doxorubicin treatment by decreasing TrkB and Bmi1 expression. [PDF]
, 2012 Acquired resistance to classical chemotherapeutics is a major obstacle in cancer treatment. Doxorubicin is frequently used in breast cancer therapy either as single-agent or in combination with other drugs like docetaxel and cyclophosphamide.
Kopp, Florian +3 more
core +11 more sources
Disease Models & Mechanisms, 2021 Extramedullary multiple myeloma (EMM) has an overall survival of 6 months and occurs in 20% of multiple myeloma (MM) patients. Genetic and epigenetic mechanisms involved in EMM and the therapeutic role of new agents for MM are not well established ...
Lourdes Farre +15 more
doaj +1 more source
The Mechanism of Warburg Effect-Induced Chemoresistance in Cancer
Frontiers in Oncology, 2021 Although chemotherapy can improve the overall survival and prognosis of cancer patients, chemoresistance remains an obstacle due to the diversity, heterogeneity, and adaptability to environmental alters in clinic.
Chang Liu, Ying Jin, Zhimin Fan
doaj +1 more source
The MicroRNA-Based Strategies to Combat Cancer Chemoresistance via Regulating Autophagy
Frontiers in Oncology, 2022 Chemoresistance frequently occurs in cancer treatment, which results in chemotherapy failure and is one of the most leading causes of cancer-related death worldwide.
Yuhe Lei +5 more
doaj +1 more source
Clinical and Translational Medicine, 2022 Background Although chemotherapy, the most widely used systemic treatment in triple‐negative breast cancer (TNBC), markedly improved the patients’ outcome, chemoresistance always occurs.
Zhenchong Xiong +7 more
doaj +1 more source
Mitochondrial determinants of chemoresistance [PDF]
Cancer Drug Resistance, 2019 Chemoresistance constitute nowadays the major contributor to therapy failure in most cancers. There are main factors that mitigate cell response to therapy, such as target organ, inherent sensitivity to the administered compound, its metabolism, drug efflux and influx or alterations on specific cellular targets, among others. We now know that intrinsic
Bokil, Ansooya, Sancho, Patricia
openaire +2 more sources